Skip to main content

Cardiac Allograft Vasculopathy

1
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
MacitentanPhase 41 trial
Active Trials
NCT05373108Completed19Est. Feb 2023
Natera
NateraAUSTIN, TX
1 program
Blood draw to measure the levels of dd-cf DNAN/A1 trial
Active Trials
NCT05756088Withdrawn0Est. Jun 2030
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Cardiac Mitochondrial Function After Heart TransplantationN/A1 trial
Active Trials
NCT04105803Unknown64Est. Mar 2024
Genentech
GenentechCA - Oceanside
1 program
Rituximab induction/conventional immunosuppressionPHASE_2
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Rituximab induction/conventional immunosuppressionPHASE_21 trial
Active Trials
NCT01278745Terminated362Est. Oct 2015
Verona Pharma
Verona PharmaUK - London
1 program
Everolimus-Eluting Bioresorbable Vascular ScaffoldPHASE_41 trial
Active Trials
NCT02377648Completed34Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Angeles TherapeuticsMacitentan
Verona PharmaEverolimus-Eluting Bioresorbable Vascular Scaffold
Allergy TherapeuticsRituximab induction/conventional immunosuppression
NateraBlood draw to measure the levels of dd-cf DNA
Novo NordiskCardiac Mitochondrial Function After Heart Transplantation

Clinical Trials (5)

Total enrollment: 479 patients across 5 trials

NCT05373108Angeles TherapeuticsMacitentan

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

Start: May 2022Est. completion: Feb 202319 patients
Phase 4Completed
NCT02377648Verona PharmaEverolimus-Eluting Bioresorbable Vascular Scaffold

Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy

Start: Jan 2015Est. completion: Dec 202034 patients
Phase 4Completed
NCT01278745Allergy TherapeuticsRituximab induction/conventional immunosuppression

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Start: Sep 2011Est. completion: Oct 2015362 patients
Phase 2Terminated
NCT05756088NateraBlood draw to measure the levels of dd-cf DNA

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

Start: Dec 2025Est. completion: Jun 20300
N/AWithdrawn
NCT04105803Novo NordiskCardiac Mitochondrial Function After Heart Transplantation

Cardiac Mitochondrial Function After Heart Transplantation

Start: Apr 2019Est. completion: Mar 202464 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.